Stockreport

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials [Yahoo! Finance]

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF Operating Expenses : Research and development expenses decreased to $73.7 million in 2023 from $84.4 million in 2022. Net Loss : The company reported a net loss of $7 [Read more]